期刊
MOLECULES
卷 26, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/molecules26113208
关键词
COX-2; neuroinflammation; BBB; PET imaging; radioligands
资金
- National Institute of Aging of the NIH [R01AG070042-01]
- Diane Goldberg Foundation (NYSPI/CUMC)
Neuroinflammation and COX-2 upregulation play important roles in degenerative brain diseases, with PET imaging being a valuable tool for assessing COX-2 induction in vivo. Promising radioligands like [11CTMI], [11C]MC1, and [18F]MTP have demonstrated BBB permeability and binding to COX-2 in the brain, showing potential for clinical translation.
Neuroinflammation and cyclooxygenase-2 (COX-2) upregulation are associated with the pathogenesis of degenerative brain diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), epilepsy, and a response to traumatic brain injury (TBI) or stroke. COX-2 is also induced in acute pain, depression, schizophrenia, various cancers, arthritis and in acute allograft rejection. Positron emission tomography (PET) imaging allows for the direct measurement of in vivo COX-2 upregulation and thereby enables disease staging, therapy evaluation and aid quantifying target occupancy of novel nonsteroidal anti-inflammatory drugs or NSAIDs. Thus far, no clinically useful radioligand is established for monitoring COX-2 induction in brain diseases due to the delay in identifying qualified COX-2-selective inhibitors entering the brain. This review examines radiolabeled COX-2 inhibitors reported in the past decade and identifies the most promising radioligands for development as clinically useful PET radioligands. Among the radioligands reported so far, the three tracers that show potential for clinical translation are, [11CTMI], [11C]MC1 and [18F]MTP. These radioligands demonstrated BBB permeablity and in vivo binding to constitutive COX-2 in the brain or induced COX-2 during neuroinflammation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据